tiprankstipranks
Advertisement
Advertisement

HALO Stock Latest News

Halozyme price target raised to $105 from $93 at Morgan Stanley
The FlyHalozyme price target raised to $105 from $93 at Morgan Stanley
2d ago
HALO
Halozyme price target raised to $105 from $96 at TD Cowen
PremiumThe Fly
Halozyme price target raised to $105 from $96 at TD Cowen
2d ago
HALO
Halozyme price target raised to $95 from $75 at Wells Fargo
PremiumThe Fly
Halozyme price target raised to $95 from $75 at Wells Fargo
2d ago
HALO
Leerink upgraded Halozyme to Outperform on growth, market leadership
PremiumThe Fly
Leerink upgraded Halozyme to Outperform on growth, market leadership
2d ago
HALO
Halozyme upgraded to Outperform from Market Perform at Leerink
PremiumThe Fly
Halozyme upgraded to Outperform from Market Perform at Leerink
2d ago
HALO
Halozyme price target raised to $93 from $92 at Citizens
PremiumThe FlyHalozyme price target raised to $93 from $92 at Citizens
2d ago
HALO
Halozyme price target raised to $115 from $95 at H.C. Wainwright
Premium
The Fly
Halozyme price target raised to $115 from $95 at H.C. Wainwright
2d ago
HALO
Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82
Premium
The Fly
Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82
3d ago
HALO
Halozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25
PremiumThe Fly
Halozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25
3d ago
HALO
Is HALO a Buy, Before Earnings?
PremiumPre-Earnings
Is HALO a Buy, Before Earnings?
5d ago
HALO
Halozyme announces global collaboration, license agreement with Incyte
PremiumThe Fly
Halozyme announces global collaboration, license agreement with Incyte
20d ago
HALO
INCY
Halozyme announces key executive leadership transition and reorganization
PremiumCompany Announcements
Halozyme announces key executive leadership transition and reorganization
1M ago
8K
HALO
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
PremiumThe FlyLifeMD partners with Halozyme subsidiary for exclusive testosterone program
2M ago
HALO
LFMD
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
Premium
Ratings
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
2M ago
HALO
Halozyme Earnings Call Highlights Royalty-Fueled Growth
Premium
Company Announcements
Halozyme Earnings Call Highlights Royalty-Fueled Growth
3M ago
HALO
Halozyme price target lowered to $93 from $96 at Morgan Stanley
PremiumThe Fly
Halozyme price target lowered to $93 from $96 at Morgan Stanley
3M ago
HALO
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
PremiumRatings
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
3M ago
HALO
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
PremiumRatings
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
3M ago
HALO
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
PremiumThe Fly
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
3M ago
HALO
Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09
PremiumThe FlyHalozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09
3M ago
HALO
HALO Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
HALO Earnings this Week: How Will it Perform?
3M ago
HALO
Halozyme Stockholders Back Board, Pay and Auditor Choices
Premium
Company Announcements
Halozyme Stockholders Back Board, Pay and Auditor Choices
3M ago
8K
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >